StockData
Sinovac Biotech Ltd logo

Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 7/30
$6.47+0.00 (0.00%)

Close on Nov 18, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $386.01M, up 6.8% from the year before. Over ten years it grew 19.1% a year on average. The highest annual figure on record is $19.37B in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$386.01M+6.8%
FY2024Dec 31, 2024$361.37M-23.1%
FY2023Dec 31, 2023$470.17M-68.1%
FY2022Dec 31, 2022$1.47B-92.4%
FY2021Dec 31, 2021$19.37B+3692.5%
FY2020Dec 31, 2020$510.62M+107.5%
FY2019Dec 31, 2019$246.05M+7.1%
FY2018Dec 31, 2018$229.65M+31.7%
FY2017Dec 31, 2017$174.35M+140.7%
FY2016Dec 31, 2016$72.43M+7.4%
FY2015Dec 31, 2015$67.41M+7.1%
FY2014Dec 31, 2014$62.93M-12.3%
FY2013Dec 31, 2013$71.77M+45.8%
FY2012Dec 31, 2012$49.22M-13.4%
FY2011Dec 31, 2011$56.84M+70.2%
FY2010Dec 31, 2010$33.40M-60.3%
FY2009Dec 31, 2009$84.20M–

More Sinovac Biotech figures

See a number that looks wrong?